Denali Therapeutics (DNLI) and Its Peers Critical Contrast
Denali Therapeutics (NASDAQ: DNLI) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Denali Therapeutics to related companies based on the strength of its valuation, dividends, analyst recommendations, risk, earnings, institutional ownership and profitability.
Valuation & Earnings
This table compares Denali Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Denali Therapeutics Competitors||$290.27 million||$35.99 million||62.30|
This table compares Denali Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Denali Therapeutics Competitors||-5,189.81%||-162.78%||-35.24%|
This is a breakdown of recent recommendations for Denali Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Denali Therapeutics Competitors||917||3335||11835||237||2.70|
Denali Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 44.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.45%. Given Denali Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Denali Therapeutics is more favorable than its peers.
Insider & Institutional Ownership
49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Denali Therapeutics beats its peers on 6 of the 11 factors compared.
Denali Therapeutics Company Profile
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.